Trial Outcomes & Findings for A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction (NCT NCT02418156)

NCT ID: NCT02418156

Last Updated: 2023-07-21

Results Overview

Proportion of patients experiencing device related adverse events.

Recruitment status

COMPLETED

Target enrollment

38 participants

Primary outcome timeframe

Up to 12 months follow-up

Results posted on

2023-07-21

Participant Flow

Participant milestones

Participant milestones
Measure
Single Arm
Observation of subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair. CorMatrix ECM for Vascular Repair: Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair.
Overall Study
STARTED
38
Overall Study
COMPLETED
21
Overall Study
NOT COMPLETED
17

Reasons for withdrawal

Reasons for withdrawal
Measure
Single Arm
Observation of subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair. CorMatrix ECM for Vascular Repair: Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair.
Overall Study
Lost to Follow-up
12
Overall Study
Death
2
Overall Study
Physician Decision
1
Overall Study
Withdrawal by Subject
1
Overall Study
Subject refused to return
1

Baseline Characteristics

A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Single Arm
n=38 Participants
Observation of subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair. CorMatrix ECM for Vascular Repair: Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair. Device performance and adverse events were collected.
Age, Categorical
<=18 years
1 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
n=5 Participants
Age, Categorical
>=65 years
22 Participants
n=5 Participants
Age, Continuous
63.7 Years
STANDARD_DEVIATION 11 • n=5 Participants
Sex: Female, Male
Female
11 Participants
n=5 Participants
Sex: Female, Male
Male
27 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
38 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
9 Participants
n=5 Participants
Race (NIH/OMB)
White
29 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
38 participants
n=5 Participants
Device Performance
45 Procedures
n=5 Participants
CoMorbidity Risk Factors
Hypertension
35 participants
n=5 Participants
CoMorbidity Risk Factors
Hyperlipidemia
26 participants
n=5 Participants
CoMorbidity Risk Factors
Diabetes
18 participants
n=5 Participants
CoMorbidity Risk Factors
Previous Vascular Surgery
20 participants
n=5 Participants
CoMorbidity Risk Factors
Active tobacco use
15 participants
n=5 Participants
CoMorbidity Risk Factors
Hx Sedentary lifestyle
12 participants
n=5 Participants
CoMorbidity Risk Factors
Family Hx of Vascular Disease
12 participants
n=5 Participants
CoMorbidity Risk Factors
Previous groin surgery
13 participants
n=5 Participants
CoMorbidity Risk Factors
Hx of CABG
10 participants
n=5 Participants
CoMorbidity Risk Factors
Previous MI
9 participants
n=5 Participants
CoMorbidity Risk Factors
Hx of renal disease
7 participants
n=5 Participants
CoMorbidity Risk Factors
Obesity
3 participants
n=5 Participants
Weight
177.3 Pounds
STANDARD_DEVIATION 37.1 • n=5 Participants
Tobacco Use
Current smoker
15 Participants
n=5 Participants
Tobacco Use
Previous smoker
18 Participants
n=5 Participants
Tobacco Use
Never
5 Participants
n=5 Participants
Indication for Surgery
Acute critical limb ischemia
7 Surgical Indications
n=5 Participants
Indication for Surgery
Claudication (Fontaine class IIb)
34 Surgical Indications
n=5 Participants
Indication for Surgery
Rest and night pain (Fontaine class III)
4 Surgical Indications
n=5 Participants
Indication for Surgery
Gangrene (Fontaine class IV)
2 Surgical Indications
n=5 Participants
Indication for Surgery
Infected prosthesis
0 Surgical Indications
n=5 Participants
Indication for Surgery
Other
2 Surgical Indications
n=5 Participants
Intervention/Procedure
Iliofemoral endarterectomy
30 Interventions/Procedures
n=5 Participants
Intervention/Procedure
Femoral endarterectomy
11 Interventions/Procedures
n=5 Participants
Intervention/Procedure
Iliofemoral endarterectomy with profundaplasty
3 Interventions/Procedures
n=5 Participants
Intervention/Procedure
Other
1 Interventions/Procedures
n=5 Participants

PRIMARY outcome

Timeframe: Up to 12 months follow-up

Population: Several participants had both limbs treated resulting in a greater number of procedures than participants analyzed.

Proportion of patients experiencing device related adverse events.

Outcome measures

Outcome measures
Measure
Single Arm
n=45 Procedures
Observation of subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair. CorMatrix ECM for Vascular Repair: Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair.
Device-Related Adverse Events
0 Proportion of Participants that Experien
Interval 0.0 to 0.0

Adverse Events

Single Arm

Serious events: 14 serious events
Other events: 0 other events
Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure
Single Arm
n=38 participants at risk
Observation of subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair. CorMatrix ECM for Vascular Repair: Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair.
Psychiatric disorders
Depression and Suicide Attempt
2.6%
1/38 • Number of events 1 • One year
Vascular disorders
Non Healing Lower Extremity Ulcer
2.6%
1/38 • Number of events 1 • One year
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Right upper lobe adenocarcinoma
2.6%
1/38 • Number of events 1 • One year
Vascular disorders
Failed Vascular Interventions/Severe PAD
2.6%
1/38 • Number of events 1 • One year
Blood and lymphatic system disorders
Coag Neg Staph Bacteremia
2.6%
1/38 • Number of events 1 • One year
Vascular disorders
Post Operative Seroma
2.6%
1/38 • Number of events 1 • One year
Vascular disorders
Critical Limb Ischemia
2.6%
1/38 • Number of events 1 • One year
Surgical and medical procedures
Pseudoaneurysm
2.6%
1/38 • Number of events 1 • One year
Cardiac disorders
Stroke-like symptoms
2.6%
1/38 • Number of events 1 • One year
Cardiac disorders
Atrial flutter & atrial fibrillation
2.6%
1/38 • Number of events 1 • One year
General disorders
Chest pain
2.6%
1/38 • Number of events 1 • One year
Gastrointestinal disorders
Abdominal pain
2.6%
1/38 • Number of events 1 • One year
Vascular disorders
Bilaterial lower extremity pain and numbness
2.6%
1/38 • Number of events 1 • One year
Cardiac disorders
CVA
2.6%
1/38 • Number of events 1 • One year

Other adverse events

Adverse event data not reported

Additional Information

Clinical Director

Aziyo Biolgics, Inc.

Phone: 470-514-4085

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60